Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Long-Term Deferred Tax: 2022-2024

Historic Long-Term Deferred Tax for ProQR Therapeutics N.V (PRQR) over the last 3 years, with Dec 2024 value amounting to $3.5 million.

  • ProQR Therapeutics N.V's Long-Term Deferred Tax fell 18.73% to $3.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.5 million, marking a year-over-year decrease of 18.73%. This contributed to the annual value of $3.5 million for FY2024, which is 19.17% down from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Long-Term Deferred Tax stood at $3.5 million for FY2024, which was down 19.17% from $4.3 million recorded in FY2023.
  • ProQR Therapeutics N.V's 5-year Long-Term Deferred Tax high stood at $4.3 million for FY2023, and its period low was $3.5 million during FY2024.
  • Over the past 3 years, ProQR Therapeutics N.V's median Long-Term Deferred Tax value was $4.0 million (recorded in 2022), while the average stood at $3.9 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first grew by 7.70% in 2023, then fell by 19.17% in 2024.
  • Yearly analysis of 3 years shows ProQR Therapeutics N.V's Long-Term Deferred Tax stood at $4.0 million in 2022, then grew by 7.70% to $4.3 million in 2023, then declined by 19.17% to $3.5 million in 2024.